MIP-1095 (TFA)

MIP-1095 (RPS-001) TFA is a potent inhibitor of PSMA with good biodistribution and efficient targeting of tumor lesions. In applications, MIP-1095 TFA will be isotopically labeled (131I labeled) as an imaging probe to indicate tumor progression. And 131I-MIP-1095 showed higher renal uptake in mice[1][2].

Product Specifications

Product Name Alternative

RPS-001 (TFA)

UNSPSC

12352005

Target

PSMA

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mip-1095-tfa.html

Purity

99.76

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C([C@H](CCC(O)=O)NC(N[C@@H](CCCCNC(NC1=CC=C(C=C1)I)=O)C(O)=O)=O)O.OC(C(F)(F)F)=O

Molecular Formula

C21H26F3IN4O10

Molecular Weight

678.35

References & Citations

[1]Zechmann CM, et al. Radiation dosimetry and first therapy results with a (124) I/ (131) I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014 Jul;41 (7) :1280-92.|[2]Kelly JM, et al. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. J Nucl Med. 2017 Sep;58 (9) :1442-1449.